BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26193703)

  • 41. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study.
    di Giuseppe R; Buijsse B; Hirche F; Wirth J; Arregui M; Westphal S; Isermann B; Hense HW; Dierkes J; Boeing H; Stangl GI; Weikert C
    J Clin Endocrinol Metab; 2014 Mar; 99(3):947-55. PubMed ID: 24423292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study.
    Lewerin C; Ljunggren Ö; Nilsson-Ehle H; Karlsson MK; Herlitz H; Lorentzon M; Ohlsson C; Mellström D
    Bone; 2017 May; 98():1-8. PubMed ID: 28212898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
    Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
    Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes.
    Dominguez JR; Shlipak MG; Whooley MA; Ix JH
    J Am Soc Nephrol; 2013 Mar; 24(4):647-54. PubMed ID: 23520205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia.
    Mace ML; Gravesen E; Nordholm A; Hofman-Bang J; Secher T; Olgaard K; Lewin E
    Kidney Int; 2017 Jul; 92(1):165-178. PubMed ID: 28341272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abnormalities in renal tubular phosphate handling in children with sickle cell disease.
    Raj VM; Freundlich M; Hamideh D; Alvarez O; Seeherunvong W; Abitbol C; Katsoufis C; Chandar J; Ruiz P; Zilleruelo G
    Pediatr Blood Cancer; 2014 Dec; 61(12):2267-70. PubMed ID: 25132581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reciprocal regulation of calcium-/phosphate-regulating hormones in cyclists during the Giro d'Italia 3-week stage race.
    Lombardi G; Corsetti R; Lanteri P; Grasso D; Vianello E; Marazzi MG; Graziani R; Colombini A; Galliera E; Corsi Romanelli MM; Banfi G
    Scand J Med Sci Sports; 2014 Oct; 24(5):779-87. PubMed ID: 23647316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD.
    Zhang LN; Yang G; Cheng C; Shen C; Cui YY; Zhang J; Zhang JJ; Shen ZX; Zeng M; Ge YF; Sun B; Yu XB; Ouyang C; Zhang B; Mao HJ; Liu J; Xing CY; Zha XM; Wang NN
    Osteoporos Int; 2015 Jan; 26(1):395-405. PubMed ID: 25224292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry.
    Eckberg K; Kramer H; Wolf M; Durazo-Arvizu R; Tayo B; Luke A; Cooper R
    Nephrol Dial Transplant; 2015 Apr; 30(4):630-5. PubMed ID: 25358495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.
    Isakova T; Cai X; Lee J; Katz R; Cauley JA; Fried LF; Hoofnagle AN; Satterfield S; Harris TB; Shlipak MG; Sarnak MJ; Ix JH;
    J Bone Miner Res; 2016 Apr; 31(4):742-8. PubMed ID: 26590361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.
    Ärnlöv J; Carlsson AC; Sundström J; Ingelsson E; Larsson A; Lind L; Larsson TE
    Clin J Am Soc Nephrol; 2013 May; 8(5):781-6. PubMed ID: 23335040
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.
    Mizuiri S; Nishizawa Y; Yamashita K; Ono K; Oda M; Usui K; Shigemoto K
    Nephrology (Carlton); 2014 Sep; 19(9):568-73. PubMed ID: 24947687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease.
    Goto S; Nakai K; Kono K; Yonekura Y; Ito J; Fujii H; Nishi S
    Clin Exp Nephrol; 2014 Dec; 18(6):925-31. PubMed ID: 24578219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease.
    Bouma-de Krijger A; Bots ML; Vervloet MG; Blankestijn PJ; Ter Wee PW; van Zuilen AD; Wetzels JF
    Nephrol Dial Transplant; 2014 Jan; 29(1):88-97. PubMed ID: 24215017
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating α-klotho levels in CKD and relationship to progression.
    Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
    Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.
    Yamashita K; Mizuiri S; Nishizawa Y; Kenichiro S; Doi S; Masaki T
    Nephrology (Carlton); 2017 Dec; 22(12):947-953. PubMed ID: 27558654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.